论文部分内容阅读
目的观察舒督补肾方治疗活动期强直性脊柱炎的临床疗效。方法将165例活动期强直性脊柱炎患者随机分为两组,对照组(80例)口服柳氮磺吡啶、醋氯芬酸胶囊,治疗组(85例)在西药基础上加用舒督补肾方,两组均治疗6个月。分别于治疗前后观察两组患者晨僵、关节疼痛情况、关节功能等临床指标,血沉、C-反应蛋白、免疫球蛋白等实验室指标,影像学变化及不良反应。结果治疗组总有效率94.12%,对照组为76.25%,治疗组优于对照组(P<0.05)。除对照组枕-墙距治疗前后无明显变化外,两组患者其他临床指标和实验室指标均较治疗前改善(P<0.05或P<0.01),且治疗组治疗后晨僵时间、外周疼痛关节数、血沉、C-反应蛋白等指标与对照组治疗后比较差异有统计学意义(P<0.05或P<0.01);治疗前后骶髂关节X线变化,两组比较差异无统计学意义(P>0.05);治疗组发生不良反应较对照组少(P<0.05)。结论舒督补肾方联合柳氮磺吡啶、醋氯芬酸胶囊治疗活动期强直性脊柱炎优于西药治疗,且不良反应少。
Objective To observe the clinical efficacy of Shu Du Bushen Recipe in treating active ankylosing spondylitis. Methods 165 cases of active ankylosing spondylitis patients were randomly divided into two groups, the control group (80 cases) oral sulfasalazine, aceclofenac capsules, the treatment group (85 cases) on the basis of western medicine plus Shudu Bushen Side, both groups were treated for 6 months. The clinical indexes such as morning stiffness, joint pain, joint function, ESR, C-reactive protein, immunoglobulin and other laboratory indexes, imaging changes and adverse reactions were observed before and after treatment. Results The total effective rate was 94.12% in the treatment group and 76.25% in the control group, which was superior to the control group (P <0.05). Except for the control group, there was no significant difference between the two groups before and after treatment (P <0.05 or P <0.01). Other clinical indexes and laboratory indexes of the two groups were better than those before treatment (P <0.05 or P <0.01) The number of joint, erythrocyte sedimentation rate, C-reactive protein and other indicators were significantly different from the control group after treatment (P <0.05 or P <0.01); before and after treatment, the changes of sacroiliac joint X-ray showed no significant difference P> 0.05). Adverse reactions in the treatment group were less than those in the control group (P <0.05). Conclusion Shudu Bushen Recipe combined with sulfasalazine and aceclofenac capsules is superior to Western medicine in treatment of active ankylosing spondylitis with less adverse reactions.